Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30226150 | 0.87 | MAPT (0.70) | MAPTLMNAGAASMN1; SMN2POLB | |
| SCHEMBL11748428 | 0.82 | GAA (0.47) | MAPTLMNAGAAMGAMSI | |
| Oxyphenisatin Acetate SCHEMBL29737232 | 0.82 | MAPT (1.00) | MAPTLMNAGAAMGAMSI | |
| Oxyphenisatin Acetate SCHEMBL555117 | 0.82 | MAPT (1.00) | MAPTLMNAGAAMGAMSI | |
| Oxyphenisatin Acetate SCHEMBL7528210 | 0.82 | MAPT (1.00) | MAPTLMNAGAAMGAMSI | |
| SCHEMBL11748423 | 0.81 | MAPT (0.45) | MAPTLMNAGAAMGAMSI | |
| SCHEMBL5481309 | 0.80 | CHRM2 (0.62) | MAPTLMNAGAAMGAMSI | |
| SCHEMBL11749979 | 0.80 | CHRM2 (0.51) | MAPTLMNAGAAMGAMSI | |
| SCHEMBL11748297 | 0.77 | MAPT (0.88) | MAPTLMNAGAAMGAMSI | |
| SCHEMBL11749977 | 0.77 | CHRM2 (0.48) | MAPTLMNAGAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | claimed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | claimed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | MAPT 1785/4885LMNA 3104/4885GAA 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.